Pharmaceutical Executive-09-01-2018

September 21, 2018

Pharm Exec talks with CSL Limited’s top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.

September 20, 2018

While definitions for “specialty drug” vary-and distribution and pricing/reimbursement factors remain complicated-this once-niche treatment market may be poised to steer the future of prescription medicine and patient care.

September 19, 2018

Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.

September 14, 2018

With specialty companies getting smarter in applying their big data insights to product marketing, the true commercial potential of machine learning and predictive modeling may soon be within reach.

September 14, 2018

How one nonprofit and its out-front leader are joining forces with industry to advance a new personalized medicine approach for cystic fibrosis patients nonsense mutations.

September 13, 2018

How low-cost drugs can succeed in the specialty pharmacy channel.

September 12, 2018

Pharm Exec’s latest company leaderboard in delivering shareholder value highlights the most critical measure of management performance-return on invested capital.

September 11, 2018

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

September 01, 2018

New Action Plan aims to streamline development, but rebates and reimbursement block market access.

September 01, 2018

Faced with looming uncertainties triggered by the upcoming Brexit, the United Kingdom’s life sciences sector, which constitutes one of the last big remaining bastions of British industry, is not about to rest on its laurels.

September 01, 2018

Click the title above to open the Pharmaceutical Executive September 2018 issue in an interactive PDF format.